Using the three markers together provides complementary information rather than a single readout. CD31 helps identify endothelial cell interactions, VE-cadherin indicates the state of endothelial junctions and vascular integrity, and CD105 adds information about transforming growth factor-β-related vascular remodeling. In tumor sections, this combination can connect vessel identification with structural and signaling changes in the surrounding tumor microenvironment.
CD31 and VE-cadherin should not be treated as interchangeable endothelial readouts. CD31 is linked to cell adhesion and endothelial cell interactions, whereas VE-cadherin reflects endothelial junctions and vascular integrity. Interpreting them together can show both whether endothelial-associated structures are present and how their junctional organization may relate to vessel condition in tumor tissue.
CD105 adds a signaling-related dimension to endothelial profiling. As a co-receptor in transforming growth factor-β signaling, it is associated with vascular remodeling, so its expression can help researchers examine changes beyond vessel identification alone. In cancer studies, that information is relevant when tumor-associated vessels and their microenvironment are being evaluated for remodeling-related processes.
Researchers can use immunostaining to examine the distribution and expression of these endothelial-associated proteins in tumor tissue. The resulting profiles help distinguish blood vessels while also assessing junctional organization and remodeling-related features. This approach supports characterization of tumor vascularization and provides molecular context for changes occurring within the tumor microenvironment.
Expression patterns can help researchers assess angiogenesis and characterize how tumor-associated vessels differ in their endothelial features. CD31 contributes information about endothelial interactions, VE-cadherin relates to vascular integrity, and CD105 reflects remodeling-associated signaling. Evaluating these signals together can clarify changes in the vasculature and their relationship to the tumor microenvironment.
Because the markers report complementary endothelial features, they can be included in investigations of antiangiogenic therapies to examine changes in tumor vascularization. Immunostaining and endothelial profiling may show how vessel-associated structures, junctional integrity, and remodeling-related characteristics are altered in the tumor tissue, helping connect treatment studies with mechanisms that influence cancer progression.